Kymera Therapeutics, Inc.
KYMR
$82.21
-$2.29-2.71%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -315.00M | -311.35M | -295.12M | -275.43M | -240.88M |
| Total Depreciation and Amortization | 8.29M | 8.31M | 8.27M | 8.11M | 7.96M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 56.45M | 54.88M | 53.00M | 46.82M | 43.84M |
| Change in Net Operating Assets | 7.69M | 15.27M | 5.92M | -30.50M | -44.98M |
| Cash from Operations | -242.58M | -232.89M | -227.93M | -251.01M | -234.06M |
| Capital Expenditure | -1.42M | -1.45M | -2.28M | -1.91M | -5.90M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -711.10M | -519.61M | -55.82M | 21.43M | -18.95M |
| Cash from Investing | -712.52M | -521.06M | -58.10M | 19.52M | -24.86M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.64M | -1.49M | -1.37M | -1.59M | -1.56M |
| Issuance of Common Stock | 1.06B | 1.04B | 317.99M | 529.62M | 285.28M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -51.90M | -51.90M | -28.36M | -28.36M | -28.36M |
| Cash from Financing | 1.01B | 990.71M | 288.26M | 499.67M | 255.35M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 54.13M | 236.76M | 2.24M | 268.18M | -3.56M |